Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
81.8 USD | +0.13% | +0.80% | -1.06% |
Apr. 26 | Medtronic Receives FDA Approval for Inceptiv Spinal Cord Stimulator to Treat Chronic Pain | MT |
Apr. 26 | Medtronic Gets FDA OK for Inceptiv Closed-Loop Spinal Cord Stimulator | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The firm trades with high earnings multiples: 23.29 times its 2024 earnings per share.
- With an enterprise value anticipated at 4.05 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.06% | 108B | C | ||
-4.07% | 184B | C+ | ||
-3.08% | 67.82B | A | ||
+3.51% | 51.05B | B- | ||
+9.20% | 44.67B | B- | ||
+3.40% | 41.78B | B+ | ||
+2.60% | 26.78B | B | ||
+4.38% | 26.59B | A- | ||
+15.23% | 25.86B | A- | ||
-0.97% | 25.03B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MDT Stock
- Ratings Medtronic plc